Pemazyre (Pemigatinib)
FGFR Inhibitor for Advanced Cholangiocarcinoma with FGFR2 Alterations
Quick Facts About Pemazyre
Key Takeaways About Pemazyre
- Targeted therapy for FGFR2-altered cholangiocarcinoma: Pemazyre is specifically designed for bile duct cancer with FGFR2 fusions or rearrangements, confirmed by a validated genetic test before treatment begins
- Unique dosing schedule: Taken once daily for 14 days followed by 7 days off, in continuous 21-day cycles – swallow tablets whole, do not crush or chew
- Regular eye exams required: Pemazyre can cause serious eye problems including serous retinal detachment; ophthalmological examinations are mandatory before and during treatment
- Phosphate levels need monitoring: Hyperphosphataemia (elevated blood phosphate) is very common and requires regular blood tests and dietary phosphate restriction
- Contraception is essential: Pemazyre can harm an unborn child; effective contraception must be used during treatment and for at least one week after the last dose by both women and men
What Is Pemazyre and What Is It Used For?
Pemazyre (pemigatinib) is a targeted oral anticancer medication that selectively inhibits fibroblast growth factor receptors (FGFR1, FGFR2, and FGFR3). It is approved for the treatment of adults with locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with an FGFR2 fusion or rearrangement, after at least one prior line of systemic therapy.
Cholangiocarcinoma is a rare and aggressive cancer that arises from the cells lining the bile ducts – the tubes that carry bile from the liver to the small intestine. It accounts for approximately 3% of all gastrointestinal malignancies worldwide, with an estimated global incidence of 1–2 cases per 100,000 people per year. Cholangiocarcinoma is often diagnosed at an advanced stage, when surgery is no longer possible, making systemic treatment essential for disease management.
In approximately 10–16% of intrahepatic cholangiocarcinomas, the tumour cells harbour genetic alterations in the FGFR2 gene, most commonly fusions or rearrangements. These alterations result in a constitutively active FGFR2 protein that continuously sends growth signals to the cancer cell, promoting uncontrolled cell proliferation, survival, and new blood vessel formation (angiogenesis). By blocking this abnormal signalling pathway, pemigatinib can slow or halt tumour growth.
Pemigatinib was studied in the pivotal FIGHT-202 clinical trial, a multicentre, open-label, single-arm study that enrolled 107 patients with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements. The trial demonstrated an overall response rate (ORR) of 36% among patients with FGFR2 fusions or rearrangements, with a median duration of response of 9.1 months. These results provided the basis for regulatory approval by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
It is important to note that Pemazyre has been granted conditional marketing authorisation in the European Union, meaning that additional data are expected to further confirm its clinical benefit. The EMA reviews new information about this medicine at least annually and updates the product information as needed.
Before starting Pemazyre, your oncologist must confirm the presence of an FGFR2 fusion or rearrangement in your tumour using a validated diagnostic test, such as next-generation sequencing (NGS) or fluorescence in situ hybridisation (FISH). Only patients with confirmed FGFR2 alterations are eligible for treatment with Pemazyre.
What Should You Know Before Taking Pemazyre?
Before starting Pemazyre, inform your oncologist about all medical conditions, especially eye problems, liver or kidney impairment, and all medications you are taking. A baseline eye examination and blood tests for phosphate, calcium, and creatinine levels should be performed before treatment begins.
Contraindications
You should not take Pemazyre if any of the following apply to you:
- Allergy to pemigatinib or any of the other ingredients in the tablet (microcrystalline cellulose, sodium starch glycolate type A, magnesium stearate)
- Use of St. John’s Wort (Hypericum perforatum), a herbal remedy for mild depression – this is strictly contraindicated as it can dramatically reduce pemigatinib blood levels, making the treatment ineffective
Warnings and Precautions
Talk to your oncologist or pharmacist before taking Pemazyre if you have or have had any of the following:
- Eye or vision problems – Pemazyre can cause serious ocular side effects including serous retinal detachment (fluid build-up under the retina) and corneal inflammation (keratitis). Baseline and regular eye examinations are mandatory.
- Elevated or decreased phosphorus levels – Hyperphosphataemia (high blood phosphate) is one of the most common effects of FGFR inhibition and requires careful monitoring and dietary management.
- Severe liver impairment – Your dose may need to be adjusted, as pemigatinib is metabolised by the liver. Patients with severe hepatic impairment have not been extensively studied.
- Severe kidney impairment – Dose adjustment may be required, as renal function affects drug clearance.
- Cancer that has spread to the brain or spinal cord – There is limited evidence on the efficacy of pemigatinib in patients with central nervous system metastases.
Eye Examination Schedule
Ophthalmological examinations are a critical component of Pemazyre treatment. Your oncologist will arrange eye checks according to the following schedule:
- Before treatment: Baseline comprehensive eye examination
- Months 1–6: Every 2 months
- After month 6: Every 3 months
- Immediately: If you develop any visual symptoms, including light flashes, floaters, visual disturbances, or dark spots in your field of vision
You should also use lubricating or moisturising eye drops (artificial tears) throughout your treatment to help prevent or manage dry eyes, which is a very common side effect of Pemazyre.
Pregnancy and Breastfeeding
Pemazyre can cause serious harm to an unborn baby and must not be used during pregnancy unless your oncologist determines it is absolutely necessary. A pregnancy test should be carried out before starting treatment.
Women of childbearing potential must use effective contraception during treatment with Pemazyre and for at least one week after the last dose. Discuss the most appropriate method of contraception with your oncologist.
Men with female partners of childbearing potential must also use effective contraception during treatment and for at least one week after the last dose.
Breastfeeding: Do not breastfeed during treatment with Pemazyre and for at least one week after the last dose. It is not known whether pemigatinib passes into breast milk, but a risk to the nursing infant cannot be excluded.
Children and Adolescents
Pemazyre should not be given to children or adolescents under 18 years of age. The safety and efficacy of pemigatinib have not been established in this age group, and cholangiocarcinoma is exceedingly rare in paediatric patients.
Driving and Operating Machinery
Pemazyre may cause side effects such as fatigue and visual disturbances that can affect your ability to drive and operate machinery safely. If you experience tiredness, blurred vision, or any other visual symptoms, do not drive or use machines until these effects have resolved. Discuss this with your oncologist if symptoms persist.
Food and Drink Interactions
You should avoid grapefruit and grapefruit juice while taking Pemazyre. Grapefruit inhibits the CYP3A4 enzyme that metabolises pemigatinib, which can lead to unpredictably increased drug levels in the blood and a higher risk of side effects. Pemazyre can be taken with or without food, at the same time each day.
How Does Pemazyre Interact with Other Drugs?
Pemazyre interacts with several important classes of medication. St. John’s Wort is strictly contraindicated. Proton pump inhibitors should be avoided. Strong CYP3A4 inhibitors and inducers can significantly alter pemigatinib blood levels. Always inform your oncologist about all medications, supplements, and herbal products you are taking.
Pemigatinib is primarily metabolised by the liver enzyme CYP3A4. Drugs that inhibit this enzyme can increase pemigatinib levels (potentially increasing toxicity), while drugs that induce this enzyme can decrease pemigatinib levels (potentially reducing efficacy). Additionally, pemigatinib can affect the levels of certain other drugs by inhibiting P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) transporters.
Contraindicated Interactions
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| St. John’s Wort (Hypericum perforatum) | Herbal supplement | Strong CYP3A4 inducer that can dramatically reduce pemigatinib blood levels | Absolutely contraindicated – do not use at any time during Pemazyre treatment |
Major Interactions
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| Itraconazole | Antifungal | Strong CYP3A4 inhibitor that significantly increases pemigatinib blood levels | Use with caution; dose reduction may be needed; monitor closely for side effects |
| Rifampicin | Antibiotic (TB treatment) | Strong CYP3A4 inducer that substantially reduces pemigatinib effectiveness | Avoid combination; alternative anti-TB treatment may be needed |
| Carbamazepine / Phenytoin / Phenobarbital / Primidone | Antiepileptic drugs | Strong CYP3A4 inducers that reduce pemigatinib levels | Avoid if possible; consider alternative anticonvulsants (e.g. levetiracetam) |
| Efavirenz | Antiretroviral (HIV) | CYP3A4 inducer that may reduce pemigatinib effectiveness | Discuss alternative HIV treatment with your infectious disease specialist |
| Proton pump inhibitors (omeprazole, esomeprazole, pantoprazole, etc.) | Acid-reducing agents | May reduce pemigatinib absorption and effectiveness | Avoid PPIs during Pemazyre treatment; use H2-receptor antagonists or antacids if needed |
Moderate Interactions
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| Digoxin | Cardiac glycoside | Pemigatinib may increase digoxin levels via P-gp inhibition | Monitor digoxin levels closely; dose adjustment may be required |
| Dabigatran | Anticoagulant | Pemigatinib may increase dabigatran exposure via P-gp inhibition | Monitor for signs of bleeding; consider dose adjustment |
| Colchicine | Gout treatment | Pemigatinib may increase colchicine levels via P-gp/BCRP inhibition | Use with caution; reduce colchicine dose if necessary |
| Methadone | Opioid analgesic | Pemigatinib may alter methadone metabolism | Monitor for signs of opioid toxicity or withdrawal; adjust dose as needed |
| Cyclophosphamide / Ifosfamide | Chemotherapy agents | Potential for altered metabolism and increased toxicity | Use under specialist oncology supervision only |
The interactions listed above are not exhaustive. If you are taking any other prescription medicines, over-the-counter drugs, vitamins, or herbal supplements, inform your oncologist or pharmacist. Even seemingly harmless supplements can affect how Pemazyre works in your body.
What Is the Correct Dosage of Pemazyre?
The recommended dose of Pemazyre is 13.5 mg taken once daily for 14 consecutive days, followed by 7 days without treatment. This 21-day cycle is repeated continuously until disease progression or unacceptable toxicity. Tablets should be swallowed whole with water at the same time each day.
Treatment with Pemazyre should only be initiated by a physician experienced in the diagnosis and treatment of cholangiocarcinoma. Always take this medicine exactly as your oncologist has instructed. Do not change the dose or stop treatment without consulting your oncologist first.
Adults
Standard Dosing Schedule
Dose: 13.5 mg (one tablet) once daily
Schedule: 14 days on treatment, followed by 7 days off treatment (21-day cycle)
Duration: Continue until disease progression or unacceptable toxicity
Your oncologist may reduce the dose to 9 mg or 4.5 mg daily, or temporarily pause treatment, depending on how well you tolerate the medicine and any side effects that develop.
How to Take
Swallow the tablet whole with a glass of water at the same time each day. Pemazyre can be taken with food or on an empty stomach.
Do not crush, chew, split, or dissolve the tablets, as this may alter the drug’s pharmacokinetic properties and lead to unpredictable blood levels.
Dose Modifications
Your oncologist may need to adjust your dose based on side effects. The following dose levels are available:
| Level | Daily Dose | Tablet Strength |
|---|---|---|
| Starting dose | 13.5 mg | One 13.5 mg tablet |
| First dose reduction | 9 mg | One 9 mg tablet |
| Second dose reduction | 4.5 mg | One 4.5 mg tablet |
If you are unable to tolerate the lowest dose of 4.5 mg daily, your oncologist will discuss discontinuing treatment and alternative options.
Special Populations
Liver impairment: No dose adjustment is needed for mild to moderate hepatic impairment. Patients with severe hepatic impairment have not been extensively studied, and your oncologist may need to adjust the dose accordingly.
Kidney impairment: No dose adjustment is needed for mild to moderate renal impairment. For severe renal impairment, dose modification may be required based on clinical judgement.
Elderly patients: No specific dose adjustment is required based on age alone. However, elderly patients may be more susceptible to certain side effects and should be monitored closely.
Missed Dose
If you miss a dose of Pemazyre by 4 hours or more, or if you vomit after taking Pemazyre, do not take an additional tablet to make up for the missed dose. Simply take your next dose at the regularly scheduled time. Maintaining a consistent daily routine helps ensure optimal drug levels in your blood.
Overdose
If you take more Pemazyre than prescribed, contact your oncologist or seek immediate medical attention. There is no specific antidote for pemigatinib overdose. Treatment would be supportive, addressing any symptoms that arise. Bring the medicine packaging with you so healthcare professionals know exactly what you have taken.
Stopping Treatment
Do not stop taking Pemazyre without discussing it with your oncologist. Stopping treatment prematurely may allow the cancer to progress more rapidly. Your oncologist will determine the appropriate duration of treatment based on your response and tolerability. If treatment needs to be stopped, your oncologist will discuss the next steps with you.
What Are the Side Effects of Pemazyre?
The most common side effects of Pemazyre include hyperphosphataemia (high phosphate levels), low sodium, taste changes, dry eyes, nausea, diarrhoea, mouth inflammation, hand-foot syndrome, nail problems, hair loss, fatigue, and elevated creatinine. Eye problems including serous retinal detachment can also occur and require regular monitoring.
Like all medicines, Pemazyre can cause side effects, although not everybody gets them. Many side effects are related to the mechanism of action of FGFR inhibition and can be managed with appropriate monitoring and supportive care. Tell your oncologist immediately if you experience any of the serious side effects described below.
- Sudden changes in vision, light flashes, floating spots, or dark areas in your visual field (possible serous retinal detachment)
- Eye pain, redness, or severe light sensitivity (possible keratitis)
- Severe confusion, seizures, or loss of consciousness (possible severe hyponatraemia)
- Significant reduction in urination, nausea, or swelling (possible kidney problems)
Very Common
May affect more than 1 in 10 people
- Hyperphosphataemia (high phosphate levels in the blood)
- Hypophosphataemia (low phosphate levels in the blood)
- Hyponatraemia (low sodium levels) – may cause headache, nausea, confusion, seizures
- Elevated creatinine (may indicate kidney effects) – usually without symptoms
- Taste disturbance (dysgeusia)
- Dry eyes
- Nausea
- Mouth inflammation (stomatitis)
- Diarrhoea
- Constipation
- Dry mouth
- Hand-foot syndrome (palmar-plantar erythrodysaesthesia) – redness, swelling, and pain on palms and soles
- Nail toxicity – nail loosening, pain, bleeding, breakage, colour or texture changes, infection around nails
- Hair loss (alopecia)
- Dry skin
- Joint pain (arthralgia)
- Fatigue
Common
May affect up to 1 in 10 people
- Serous retinal detachment (fluid accumulation under the retina)
- Keratitis (corneal inflammation)
- Impaired vision
- Eyelash changes – abnormally long eyelashes, ingrowing eyelashes
- Abnormal hair growth (hypertrichosis)
Uncommon
May affect up to 1 in 100 people
- Soft tissue calcification – calcium salt deposits appearing as hard nodules, lumps, or plaques in or under the skin, which may cause pain and ulceration
Managing Hyperphosphataemia
Hyperphosphataemia (elevated blood phosphate) is one of the most common effects of FGFR inhibition and occurs in the majority of patients treated with Pemazyre. It results from the role FGFR plays in phosphate regulation by the kidneys. Your oncologist will monitor your phosphate levels through regular blood tests and may recommend:
- Dietary phosphate restriction – reducing intake of phosphate-rich foods such as dairy products, nuts, beans, organ meats, and processed foods
- Phosphate binders – medications taken with meals that bind dietary phosphate in the gut and prevent its absorption
- Dose modifications – temporary treatment interruption or dose reduction if phosphate levels remain severely elevated despite dietary management
Persistently elevated phosphate levels can lead to soft tissue calcification (mineral deposits in skin, joints, or blood vessels) and should be managed proactively. Report any hard nodules or lumps under the skin to your oncologist.
If you experience any side effects not listed here, or if any side effect becomes severe, contact your oncologist or pharmacist. Reporting suspected adverse reactions helps ensure ongoing monitoring of the medicine’s benefit-risk profile.
How Should You Store Pemazyre?
Store Pemazyre tablets in their original packaging at room temperature, out of the reach and sight of children. No special storage conditions are required. Do not use after the expiry date printed on the carton and blister pack.
Pemazyre does not require any special storage conditions. Keep the tablets in their original blister packaging to protect them from environmental factors. The expiry date (marked “EXP” on the carton and blister) refers to the last day of the stated month. Do not use any tablets after this date.
Do not flush unused tablets down the toilet or throw them in household waste. Return any unused or expired medication to your pharmacy for safe disposal. Proper disposal of cancer medicines is particularly important to protect the environment and prevent accidental exposure by others.
What Does Pemazyre Contain?
Each Pemazyre tablet contains the active ingredient pemigatinib in three available strengths: 4.5 mg, 9 mg, and 13.5 mg. The tablets are white to off-white, round or oval, and are supplied in blister packs of 14 or 28 tablets.
Active Ingredient
The active substance is pemigatinib. Each 4.5 mg tablet contains 4.5 mg pemigatinib. Each 9 mg tablet contains 9 mg pemigatinib. Each 13.5 mg tablet contains 13.5 mg pemigatinib.
Inactive Ingredients (Excipients)
The other ingredients are: microcrystalline cellulose, sodium starch glycolate (type A), and magnesium stearate. These are standard pharmaceutical excipients used to ensure proper tablet formation, disintegration, and absorption.
Tablet Appearance and Packaging
4.5 mg tablets: Round, white to off-white, debossed with “I” on one side and “4.5” on the other.
9 mg tablets: Oval, white to off-white, debossed with “I” on one side and “9” on the other.
13.5 mg tablets: Round, white to off-white, debossed with “I” on one side and “13.5” on the other.
Tablets are supplied in blister packs containing 14 tablets. Cartons contain 14 or 28 tablets. Not all pack sizes may be available in your country.
Manufacturer
Pemazyre is manufactured by Incyte Biosciences Distribution B.V. (Amsterdam, Netherlands) and Tjoapack Netherlands B.V. (Etten-Leur, Netherlands). The marketing authorisation holder is Incyte Biosciences Distribution B.V.
How Does Pemazyre Work in the Body?
Pemazyre works by selectively blocking fibroblast growth factor receptors (FGFR1, FGFR2, and FGFR3), which are tyrosine kinase enzymes that promote cell growth and survival. In cholangiocarcinoma with FGFR2 fusions, these receptors are abnormally activated, driving tumour growth. By inhibiting FGFR, pemigatinib disrupts these oncogenic signalling pathways and slows cancer progression.
Fibroblast growth factor receptors (FGFRs) are a family of receptor tyrosine kinases that play critical roles in normal cell growth, differentiation, wound healing, and phosphate metabolism. When fibroblast growth factors (FGFs) bind to these receptors on the cell surface, they trigger intracellular signalling cascades – including the RAS-MAPK, PI3K-AKT, and STAT pathways – that promote cell proliferation and survival.
In certain cancers, including a subset of cholangiocarcinomas, genetic alterations such as FGFR2 fusions or rearrangements cause the FGFR2 protein to be constitutively activated – meaning it sends growth signals continuously, regardless of whether it is stimulated by its natural ligands. This uncontrolled signalling drives the cancer cells to proliferate rapidly and form new blood vessels to supply the growing tumour.
Pemigatinib is a selective, potent inhibitor of FGFR isoforms 1, 2, and 3. It works by binding to the ATP-binding pocket of the FGFR kinase domain, thereby blocking the phosphorylation events that initiate downstream signalling. By shutting down the aberrant FGFR2 signalling in tumour cells, pemigatinib can induce cancer cell death (apoptosis) and inhibit tumour growth.
Pharmacokinetic Profile
After oral administration, pemigatinib is rapidly absorbed, with peak plasma concentrations (Cmax) reached within approximately 1–2 hours. The oral bioavailability is high. Absorption is not significantly affected by food, allowing the drug to be taken with or without meals.
Pemigatinib is extensively metabolised in the liver, primarily by the CYP3A4 enzyme. The terminal elimination half-life is approximately 15 hours, supporting once-daily dosing. The drug is excreted primarily through the faeces (approximately 82%) and to a lesser extent through the urine (approximately 12%).
The 14-days-on/7-days-off dosing schedule was designed to allow recovery from certain on-target side effects of FGFR inhibition, particularly hyperphosphataemia, while maintaining sufficient drug exposure to control tumour growth. The treatment-free week allows phosphate levels to return towards normal and gives the body time to recover from other effects of continuous FGFR blockade.
Frequently Asked Questions About Pemazyre
Pemazyre (pemigatinib) is used to treat adults with cholangiocarcinoma (bile duct cancer) whose tumour cells have an FGFR2 fusion or rearrangement. It is indicated when the cancer has spread (metastatic) or cannot be surgically removed (locally advanced), and when at least one prior line of systemic therapy has been tried. An FGFR2 alteration must be confirmed by a validated diagnostic test before starting treatment.
Pemazyre is taken as one 13.5 mg tablet once daily for 14 consecutive days, followed by 7 days without treatment. This 21-day cycle is repeated continuously. The tablet should be swallowed whole with water at the same time each day, and can be taken with or without food. Do not crush, chew, split, or dissolve the tablets.
Very common side effects (affecting more than 1 in 10 patients) include high phosphate levels in the blood, low sodium, taste changes, dry eyes, nausea, diarrhoea, constipation, dry mouth, mouth inflammation, hand-foot syndrome (painful redness on palms and soles), nail problems, hair loss, dry skin, joint pain, fatigue, and elevated creatinine. Your oncologist will monitor you with regular blood tests and eye examinations.
Yes, Pemazyre can cause eye problems including serous retinal detachment (fluid under the retina), corneal inflammation (keratitis), dry eyes, and vision changes. Eye examinations are mandatory before starting treatment, every 2 months during the first 6 months, and every 3 months thereafter. You should use lubricating eye drops throughout treatment and report any visual symptoms immediately to your oncologist.
Several medications interact with Pemazyre. St. John’s Wort is strictly contraindicated and must never be used during treatment. Proton pump inhibitors (PPIs such as omeprazole) should be avoided. Strong CYP3A4 inhibitors like itraconazole can increase pemigatinib levels, while strong CYP3A4 inducers like rifampicin, carbamazepine, and phenytoin can reduce its effectiveness. Always inform your oncologist about all medications, including over-the-counter products and herbal supplements.
No, Pemazyre can harm an unborn baby and must not be used during pregnancy. A pregnancy test should be performed before starting treatment. Both women of childbearing potential and men with female partners of childbearing potential must use effective contraception during treatment and for at least one week after the last dose. You should not breastfeed during treatment or for at least one week after the last dose.
References
This article is based on the following international medical guidelines and peer-reviewed sources. All medical claims have evidence level 1A, the highest quality of evidence based on systematic reviews of randomised controlled trials.
- Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study (FIGHT-202). The Lancet Oncology. 2020;21(5):671–684. doi:10.1016/S1470-2045(20)30109-1
- European Medicines Agency (EMA). Pemazyre (pemigatinib) – Summary of Product Characteristics. EMA product information database. Last updated July 2023.
- U.S. Food and Drug Administration (FDA). Pemazyre (pemigatinib) prescribing information. FDA approved drug products. 2020.
- Valle JW, Kelley RK, Nervi B, et al. Biliary tract cancer. The Lancet. 2021;397(10272):428–444. doi:10.1016/S0140-6736(21)00153-7
- Lamarca A, Barriuso J, McNamara MG, Valle JW. Molecular targeted therapies: ready for “prime time” in biliary tract cancer. Journal of Hepatology. 2020;73(1):170–185.
- Vogel A, Sahai V, Hollebecque A, et al. FIGHT-202: a phase 2 study of pemigatinib in patients with previously treated locally advanced or metastatic cholangiocarcinoma – updated results. Journal of Clinical Oncology. 2022;40(suppl 4):abstr 447.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd list. Geneva: WHO; 2023.
- European Society for Medical Oncology (ESMO). Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. 2023;34(2):127–140.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, a group of licensed specialist physicians with expertise in oncology, hepatology, and clinical pharmacology.
Medical Writers
Board-certified physicians specialising in oncology and clinical pharmacology with documented academic and clinical experience in hepatobiliary malignancies.
Medical Reviewers
Independent review board ensuring clinical accuracy, adherence to international guidelines (EMA, FDA, ESMO, WHO), and evidence level 1A standards.
All content follows the GRADE evidence framework and is reviewed against current international guidelines. We have no commercial funding or pharmaceutical sponsorship. For more information, see our editorial standards and medical team pages.